HRP20171024T1 - Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti - Google Patents
Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti Download PDFInfo
- Publication number
- HRP20171024T1 HRP20171024T1 HRP20171024TT HRP20171024T HRP20171024T1 HR P20171024 T1 HRP20171024 T1 HR P20171024T1 HR P20171024T T HRP20171024T T HR P20171024TT HR P20171024 T HRP20171024 T HR P20171024T HR P20171024 T1 HRP20171024 T1 HR P20171024T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- intended
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 7
- 238000011282 treatment Methods 0.000 title claims 3
- 230000003412 degenerative effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000008414 cartilage metabolism Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (5)
1. Spoj prema Formuli I:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju, sprječavanju ili profilaksi osteoartritisa, alergijske bolesti dišnih puteva ili upalnih bolesti crijeva.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je stanje osteoartritis.
3. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je stanje upalne bolesti crijeva.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, primijenjuje u kombinaciji s dodatnim terapijskim sredstvom.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je dodatno terapijsko sredstvo sredstvo za liječenje, sprječavanje ili profilaksu upalnih stanja, autoimunih bolesti, proliferativnih bolesti, odbacivanja presatka, bolesti koje uključuju poremećaj metabolizma hrskavice ili urođenih malformacija hrskavice.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22068509P | 2009-06-26 | 2009-06-26 | |
| US29818810P | 2010-01-25 | 2010-01-25 | |
| EP14175887.0A EP2792677B1 (en) | 2009-06-26 | 2010-06-25 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171024T1 true HRP20171024T1 (hr) | 2017-10-06 |
Family
ID=42340530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141057AT HRP20141057T1 (en) | 2009-06-26 | 2014-11-03 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| HRP20171024TT HRP20171024T1 (hr) | 2009-06-26 | 2017-07-04 | Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141057AT HRP20141057T1 (en) | 2009-06-26 | 2014-11-03 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8796457B2 (hr) |
| EP (2) | EP2445912B1 (hr) |
| JP (1) | JP5486084B2 (hr) |
| KR (1) | KR101712561B1 (hr) |
| CN (1) | CN102459261B (hr) |
| AR (1) | AR077221A1 (hr) |
| AU (1) | AU2010264635B2 (hr) |
| BR (1) | BRPI1014759A2 (hr) |
| CA (1) | CA2765988C (hr) |
| CL (1) | CL2011003276A1 (hr) |
| CO (1) | CO6491039A2 (hr) |
| CR (1) | CR20110673A (hr) |
| CY (1) | CY1119711T1 (hr) |
| DK (2) | DK2445912T3 (hr) |
| DO (1) | DOP2011000378A (hr) |
| EA (1) | EA020111B1 (hr) |
| ES (2) | ES2634325T3 (hr) |
| HK (2) | HK1168098A1 (hr) |
| HR (2) | HRP20141057T1 (hr) |
| HU (1) | HUE034205T2 (hr) |
| IL (1) | IL216618A (hr) |
| JO (1) | JO3030B1 (hr) |
| LT (1) | LT2792677T (hr) |
| MA (1) | MA33447B1 (hr) |
| ME (1) | ME01916B (hr) |
| MX (1) | MX2011013451A (hr) |
| NZ (1) | NZ596836A (hr) |
| PE (1) | PE20120494A1 (hr) |
| PL (2) | PL2445912T3 (hr) |
| PT (2) | PT2445912E (hr) |
| RS (1) | RS53617B1 (hr) |
| SG (1) | SG177359A1 (hr) |
| SI (2) | SI2445912T1 (hr) |
| SM (1) | SMT201400169B (hr) |
| TW (1) | TWI469981B (hr) |
| UY (1) | UY32741A (hr) |
| WO (1) | WO2010149771A1 (hr) |
| ZA (1) | ZA201109502B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2696869B1 (en) | 2011-04-12 | 2017-08-23 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| US9284311B2 (en) * | 2012-06-22 | 2016-03-15 | Galapagos Nv | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| EP3041841B1 (en) | 2013-09-05 | 2019-06-05 | F. Hoffmann-La Roche AG | Triazolopyridine compounds, compositions and methods of use thereof |
| TN2016000227A1 (fr) | 2013-12-05 | 2017-10-06 | Pfizer | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides. |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6898249B2 (ja) * | 2015-04-13 | 2021-07-07 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 心臓血管障害の治療のための方法 |
| JP6978097B2 (ja) | 2016-07-26 | 2021-12-08 | スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. | Ｊａｋ阻害剤としての複素環化合物、該化合物の塩類および治療への使用 |
| CN111479810B (zh) * | 2018-01-31 | 2022-11-22 | 珠海联邦制药股份有限公司 | Jak抑制剂及其应用 |
| CN112955222A (zh) | 2018-08-29 | 2021-06-11 | 里珍纳龙药品有限公司 | 用于治疗患有类风湿性关节炎的个体的方法和组合物 |
| CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
| CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE283840T1 (de) | 1999-01-29 | 2004-12-15 | Chugai Pharmaceutical Co Ltd | Chondrogonese promotoren und indolin-2-on derivate |
| EP1391211A1 (en) | 2001-04-27 | 2004-02-25 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| AU2003231880A1 (en) * | 2002-05-30 | 2003-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
| CA2515190A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| EP1759203A2 (en) | 2004-06-21 | 2007-03-07 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| CA2577478A1 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| CA2582482A1 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| AU2007291190A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| CA2689514C (en) | 2007-06-05 | 2015-09-29 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
| JP2010533680A (ja) | 2007-07-18 | 2010-10-28 | ノバルティス アーゲー | 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用 |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| AU2008291075A1 (en) | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
| AU2009259867A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
-
2010
- 2010-05-31 JO JOP/2010/0179A patent/JO3030B1/ar active
- 2010-06-23 TW TW99120587A patent/TWI469981B/zh not_active IP Right Cessation
- 2010-06-24 AR ARP100102236A patent/AR077221A1/es active IP Right Grant
- 2010-06-25 UY UY0001032741A patent/UY32741A/es not_active Application Discontinuation
- 2010-06-25 AU AU2010264635A patent/AU2010264635B2/en not_active Ceased
- 2010-06-25 EA EA201270076A patent/EA020111B1/ru not_active IP Right Cessation
- 2010-06-25 ES ES14175887.0T patent/ES2634325T3/es active Active
- 2010-06-25 PT PT107286486T patent/PT2445912E/pt unknown
- 2010-06-25 DK DK10728648.6T patent/DK2445912T3/da active
- 2010-06-25 ES ES10728648.6T patent/ES2519170T3/es active Active
- 2010-06-25 RS RS20140614A patent/RS53617B1/en unknown
- 2010-06-25 WO PCT/EP2010/059067 patent/WO2010149771A1/en active Application Filing
- 2010-06-25 PL PL10728648T patent/PL2445912T3/pl unknown
- 2010-06-25 HU HUE14175887A patent/HUE034205T2/en unknown
- 2010-06-25 EP EP10728648.6A patent/EP2445912B1/en active Active
- 2010-06-25 PE PE2011002144A patent/PE20120494A1/es active IP Right Grant
- 2010-06-25 DK DK14175887.0T patent/DK2792677T3/en active
- 2010-06-25 JP JP2012516762A patent/JP5486084B2/ja active Active
- 2010-06-25 MX MX2011013451A patent/MX2011013451A/es active IP Right Grant
- 2010-06-25 SI SI201030775T patent/SI2445912T1/sl unknown
- 2010-06-25 MA MA34555A patent/MA33447B1/fr unknown
- 2010-06-25 LT LTEP14175887.0T patent/LT2792677T/lt unknown
- 2010-06-25 SG SG2011096179A patent/SG177359A1/en unknown
- 2010-06-25 SI SI201031494T patent/SI2792677T1/sl unknown
- 2010-06-25 EP EP14175887.0A patent/EP2792677B1/en active Active
- 2010-06-25 ME MEP-2014-132A patent/ME01916B/me unknown
- 2010-06-25 NZ NZ596836A patent/NZ596836A/xx not_active IP Right Cessation
- 2010-06-25 US US12/823,682 patent/US8796457B2/en active Active
- 2010-06-25 BR BRPI1014759A patent/BRPI1014759A2/pt active Search and Examination
- 2010-06-25 CN CN201080028413.0A patent/CN102459261B/zh active Active
- 2010-06-25 KR KR1020127002060A patent/KR101712561B1/ko active IP Right Grant
- 2010-06-25 PL PL14175887T patent/PL2792677T3/pl unknown
- 2010-06-25 CA CA2765988A patent/CA2765988C/en not_active Expired - Fee Related
- 2010-06-25 PT PT141758870T patent/PT2792677T/pt unknown
-
2011
- 2011-11-27 IL IL216618A patent/IL216618A/en not_active IP Right Cessation
- 2011-12-06 DO DO2011000378A patent/DOP2011000378A/es unknown
- 2011-12-14 CR CR20110673A patent/CR20110673A/es unknown
- 2011-12-22 CL CL2011003276A patent/CL2011003276A1/es unknown
- 2011-12-22 ZA ZA2011/09502A patent/ZA201109502B/en unknown
-
2012
- 2012-01-16 CO CO12005375A patent/CO6491039A2/es active IP Right Grant
- 2012-09-11 HK HK12108855.3A patent/HK1168098A1/xx not_active IP Right Cessation
- 2012-09-11 HK HK15103046.1A patent/HK1202537A1/xx not_active IP Right Cessation
-
2014
- 2014-08-04 US US14/451,127 patent/US9505754B2/en active Active
- 2014-11-03 HR HRP20141057AT patent/HRP20141057T1/hr unknown
- 2014-11-10 SM SM201400169T patent/SMT201400169B/xx unknown
-
2017
- 2017-07-04 HR HRP20171024TT patent/HRP20171024T1/hr unknown
- 2017-07-24 CY CY20171100784T patent/CY1119711T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171024T1 (hr) | Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti | |
| HRP20201243T1 (hr) | N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala | |
| IL221764A (en) | Use of bile acid sulfate to make pharmaceutical preparations for the treatment of fxr-related diseases | |
| IL209121A (en) | Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases | |
| EP3252057A3 (en) | Multicyclic compounds and methods of use thereof | |
| IL225519A0 (en) | Effective preparations and methods for the treatment and diagnosis of inflammatory bowel disease | |
| IL233869A0 (en) | Modified tricyclic acid derivatives as p1 s 1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | |
| HK1157770A1 (en) | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| IL210803A0 (en) | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases | |
| IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
| EP2268647A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| IL200549A0 (en) | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | |
| HRP20190926T1 (hr) | Pripravci koji sadrže pirolidonkarboksilnu kiselinu (pca) i njene metalne soli | |
| IL204723A0 (en) | Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases | |
| IL190841A0 (en) | Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions | |
| PL2429507T3 (pl) | Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry | |
| IN2015DN02894A (hr) | ||
| HK1221905A1 (zh) | 作爲用於炎性腸病和/或腸易激綜合征的治療的應用 | |
| PL2182948T3 (pl) | Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR | |
| IT1393945B1 (it) | Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche | |
| IL218126A (en) | 4-phenyl-6-methyl-h5-pyrrolo [2,3- d] pyrimidine and its use in the preparation of pharmaceutical preparations for the treatment of liver and respiratory diseases | |
| PL2654897T3 (pl) | Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt | |
| PL2266557T3 (pl) | Kombinacja pochodnej benzofenonu lub jej soli oraz środka immunosupresyjnego i kompozycja farmaceutyczna zawierająca te składniki | |
| WO2007108004A3 (en) | S-alkylisothiouronium derivatives for the treatment of inflammatory diseases |